[Langerhans cell histiocytoses: 50 years to histiocytosis X].
Histiocytoses encompass a heterogeneous group of histiocytic disorders that may be separated in a group of variable biological behaviour and in a clearly malignant group. The histopathologic diagnosis of all types of histiocytoses is always mandatory. The 50-year-old Histiocytosis X compiles a subgroup of different biological behaviour, nowadays called Langerhans cell histiocytoses--the subject of the review. It has a wide range of manifestations: self-healing cutaneous, benign solitary and malignant systemic manifestations require the staging in order to evaluate a possibly necessary therapy. Chemotherapy should be performed within international protocols.
Fluri
S
S
Medizinische Universitäts-Kinderklinik, Inselspital Bern.
Gebbers
J O
JO
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006646:Histiocytosis, Langerhans-Cell / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D006651:Histocytochemistry; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008854:Microscopy, Electron; D011379:Prognosis; D011879:Radiotherapy Dosage
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents